180 related articles for article (PubMed ID: 37773003)
1. Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Ghazipura M; Macrea M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Feb; 21(2):328-337. PubMed ID: 37773003
[No Abstract] [Full Text] [Related]
2. Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Barnes H; Ghazipura M; Herman D; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Jan; 21(1):122-135. PubMed ID: 37772975
[No Abstract] [Full Text] [Related]
3. Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: Systematic Reviews and Meta-analysis.
Herman D; Ghazipura M; Barnes H; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Mar; 21(3):474-485. PubMed ID: 37773000
[No Abstract] [Full Text] [Related]
4. Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Herman D; Ghazipura M; Barnes H; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Jan; 21(1):136-150. PubMed ID: 37027538
[No Abstract] [Full Text] [Related]
5. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Macrea M; Ghazipura M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Feb; 21(2):317-327. PubMed ID: 37772987
[No Abstract] [Full Text] [Related]
7. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
9. Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial.
Bernstein EJ; Denton CP; Huang S; Khanna D
Semin Arthritis Rheum; 2024 Apr; 65():152376. PubMed ID: 38244446
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
[TBL] [Abstract][Full Text] [Related]
11. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
[TBL] [Abstract][Full Text] [Related]
12. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.
Roofeh D; Barratt SL; Wells AU; Kawano-Dourado L; Tashkin D; Strand V; Seibold J; Proudman S; Brown KK; Dellaripa PF; Doyle T; Leonard T; Matteson EL; Oddis CV; Solomon JJ; Sparks JA; Vassallo R; Maxwell L; Beaton D; Christensen R; Townsend W; Khanna D
Semin Arthritis Rheum; 2021 Dec; 51(6):1331-1341. PubMed ID: 34493396
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review.
Petelytska L; Bonomi F; Cannistrà C; Fiorentini E; Peretti S; Torracchi S; Bernardini P; Coccia C; De Luca R; Economou A; Levani J; Matucci-Cerinic M; Distler O; Bruni C
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37940340
[No Abstract] [Full Text] [Related]
14. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
Ghuman A; Khanna D; Lin CJF; Furst DE; Raghu G; Martinez FJ; Zucchetto M; Huang S; Jennings A; Nihtyanova SI; Denton CP
Rheumatology (Oxford); 2024 Feb; 63(2):472-481. PubMed ID: 37228011
[TBL] [Abstract][Full Text] [Related]
15. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
[TBL] [Abstract][Full Text] [Related]
16. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
Roofeh D; Lin CJF; Goldin J; Kim GH; Furst DE; Denton CP; Huang S; Khanna D;
Arthritis Rheumatol; 2021 Jul; 73(7):1301-1310. PubMed ID: 33538094
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.
Kuwana M; Takehara K; Tanaka Y; Yamashita K; Katsumata K; Takata M; Shima Y
Mod Rheumatol; 2024 Mar; 34(3):530-540. PubMed ID: 37436828
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
[TBL] [Abstract][Full Text] [Related]
20. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
